After plotting a course to grow by leveraging its biosimilar expertise, Sandoz has inked a deal to get involved in one of the industry's next major biosim debuts.Monday, Sandoz said it signed a deal to commercialize Samsung Bioepis' biosimilar version of Johnson & Johnson's blockbuster immunology med Stelara.

在制定了利用其生物仿制药专业知识发展的课程之后，Sandoz已经达成了一系列协议，参与了该行业下一个主要的生物制药行业之一。周一，Sandoz表示，它签署了一项协议，将三星Bioepis的强生重磅炸弹immunology med Stelara的生物仿制药版本商业化。

The deal covers commercial rights to the product in the U.S., Canada, Switzerland, the U.K. and countries in Europe.Other terms of the contract are confidential, Sandoz said in a statement.With the Stelara biosim rights locked up, Sandoz looks forward to five “potential high-value upcoming launches over the next few years,' CEO Richard Saynor said in a statement.

Sandoz在一份声明中说，该协议涵盖了美国，加拿大，瑞士，英国和欧洲国家对该产品的商业权利。合同的其他条款是保密的。首席执行官理查德·萨诺（Richard Saynor）在一份声明中说，随着Stelara biosim权利的锁定，Sandoz期待在未来几年内推出五项“潜在的高价值即将推出”。

Those include biosimilars to Biogen’s Tysabri and Regeneron and Bayer’s Eylea..

其中包括Biogen的Tysabri和Regeneron以及Bayer的Eylea的生物仿制药。。

Related

相关的

Sandoz reveals plan to boost global biosim uptake, starting in the Americas

Sandoz透露了从美洲开始提高全球biosim吸收率的计划

Stelara is Johnson & Johnson’s top revenue producer and treats several inflammatory diseases including Crohn’s disease, plaque psoriasis, psoriatic arthritis and ulcerative colitis. The IL-12/23 inhibitor brought in $9.7 billion for J&J last year.With its patents expiring later this year, the drug is a major target for generic and biosimilar companies.

Stelara是强生公司的最大收入生产商，治疗多种炎症性疾病，包括克罗恩病，斑块状银屑病，银屑病关节炎和溃疡性结肠炎。IL-12/23抑制剂去年为J＆J带来了97亿美元。随着专利今年晚些时候到期，该药成为仿制药和生物仿制药公司的主要目标。

As the patent cliff nears, J&J has been busy striking settlements specifying possible market entry dates for some of the biosim players.As it stands, Amgen holds the earliest Stelara biosimilar launch date under a J&J settlement. Back in May, the companies inked a patent settlement that grants Amgen rights to launch its copycat on January 1, 2025.And this summer, J&J signed an agreement with Alvotech and Teva that allows the partners to launch their biosimilar by Feb.

随着专利悬崖的临近，J＆J一直在忙着惊人的定居点，为一些biosim玩家指定可能的市场准入日期。就目前而言，安进拥有J＆J定居点最早的Stelara生物仿制药发射日期。早在5月，这些公司就2025年1月1日签署了一项专利解决方案，授予安进有权推出其复制品。今年夏天，J＆J与Alvotech和Teva签署了一项协议，允许合作伙伴在2月前推出其生物仿制药。

21, 2025. Lastly, Fresenius Kabi and Formycon last month signed a deal with J&J to launch their biosimilar 'no later than' April 15, 2025.Importantly, none of the Stelara biosimilars have won FDA approvals. .

212025。最后，Fresenius Kabi和Formycon上个月与J＆J签署了一份协议，不迟于2025年4月15日推出他们的生物仿制药。重要的是，没有一种Stelara生物仿制药获得FDA批准。 .

Related

相关的

Biosims generating $8B+ in annual savings, and a 'decade of growth' is ahead: analyst

Biosims每年节省8亿美元以上，“十年增长”领先：分析师

Meanwhile, Sandoz will officially split from Novartis on Oct. 4. Despite its recent history of revenue declines, the company is aiming for $3 billion in sales growth over the next five years thanks in part to its deep biosimilar pipeline.

与此同时，Sandoz将于10月4日正式从诺华分裂。尽管近期收入下降，但由于其深层生物仿制药管道，该公司未来五年的销售增长目标为30亿美元。